BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $11,864,362.28 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 326,932 shares of BridgeBio Pharma stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $36.29, for a total transaction of $11,864,362.28. Following the completion of the sale, the chief executive officer now owns 5,371,515 shares in the company, valued at approximately $194,932,279.35. This trade represents a 5.74 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Neil Kumar also recently made the following trade(s):

• On Tuesday, November 19th, Neil Kumar sold 27,389 shares of BridgeBio Pharma stock. The shares were sold at an average price of $22.41, for a total value of $613,787.49.

BridgeBio Pharma Stock Down 9.3 %

BridgeBio Pharma stock traded down $3.18 on Monday, hitting $31.03. The company's stock had a trading volume of 5,108,511 shares, compared to its average volume of 3,015,639. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $41.04. The firm has a market cap of $5.86 billion, a P/E ratio of -12.88 and a beta of 1.05. The company has a fifty day moving average price of $30.11 and a 200-day moving average price of $27.19.

Analyst Upgrades and Downgrades

BBIO has been the subject of several recent research reports. Bank of America raised their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, November 25th. HC Wainwright reiterated a "buy" rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research report on Monday, December 16th. Evercore ISI upped their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a research note on Monday, December 23rd. Leerink Partners lowered their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. Finally, Scotiabank boosted their price objective on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the stock a "sector outperform" rating in a report on Monday, November 25th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, BridgeBio Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $49.00.

Hedge Funds Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Values First Advisors Inc. bought a new stake in shares of BridgeBio Pharma during the 3rd quarter valued at approximately $57,000. CWM LLC grew its stake in shares of BridgeBio Pharma by 132.9% in the 3rd quarter. CWM LLC now owns 3,442 shares of the company's stock worth $88,000 after acquiring an additional 1,964 shares in the last quarter. Advisors Asset Management Inc. grew its holdings in shares of BridgeBio Pharma by 56.1% in the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company's stock valued at $117,000 after acquiring an additional 1,645 shares in the last quarter. Amalgamated Bank increased its position in shares of BridgeBio Pharma by 24.7% during the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company's stock valued at $123,000 after purchasing an additional 962 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in BridgeBio Pharma by 17.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,322 shares of the company's stock valued at $135,000 after acquiring an additional 801 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.